Company unveils a strategic initiative to build the world’s first known foundation model for human motion in physical rehabilitation

公司推出了一项战略举措，旨在构建全球首个已知的用于物理康复的人体运动基础模型。

Collaboration represents an important step toward integrating powerful new AI capabilities into Ekso Bionics’ proprietary exoskeleton technology platforms

协作代表着将强大的新人工智能能力整合到Ekso Bionics专有的外骨骼技术平台的重要一步。

SAN RAFAEL, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics” or the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced its acceptance into the NVIDIA Connect program. The Company plans to use the valuable tools and resources provided through this prestigious .

加利福尼亚州圣拉斐尔，2025年5月15日（环球新闻社）——Ekso Bionics Holdings, Inc.（纳斯达克股票代码：EKSO）（“Ekso Bionics”或“公司”），作为医疗和工业用途外骨骼技术的行业领导者，今天宣布其已被接受加入NVIDIA Connect计划。公司计划利用通过这一享有盛誉的计划提供的宝贵工具和资源。

NVIDIA

英伟达

program to support a new strategic initiative to build a proprietary foundation model for human motion, and to help develop and integrate related new artificial intelligence (“AI”) capabilities across its portfolio of Enterprise Health and Personal Health devices.

支持新的战略计划的项目，以构建专属的人体运动基础模型，并协助开发和整合与其企业健康和个人健康设备组合相关的新人工智能（“AI”）功能。

NVIDIA Connect is a selective program that brings together emerging and established technology companies to accelerate product development and increase cost efficiency. Members gain specialized training, priority engineering support, and exclusive access to NVIDIA’s advanced development kits, GPU platforms, and global ecosystem, helping facilitate the program members’ ability to deliver next-generation solutions in AI and high-performance computing..

NVIDIA Connect 是一项甄选计划，汇聚新兴和成熟的技术公司，以加速产品开发并提高成本效益。成员可获得专业培训、优先工程支持，并独享 NVIDIA 先进开发套件、GPU 平台及全球生态系统的访问权限，助力计划成员交付下一代人工智能和高性能计算解决方案。

“We are privileged to join a select group of medical device innovators in the NVIDIA Connect program,” said Scott Davis, Chief Executive Officer of Ekso Bionics. “While our advanced exoskeleton technology platforms are already state-of-the-art, in some ways we are only just approaching the starting line as we work to build and leverage what we believe will be the industry’s first known foundation model for human motion in physical rehabilitation.

“我们很荣幸能够加入NVIDIA Connect计划中的精选医疗设备创新者行列，”Ekso Bionics首席执行官Scott Davis表示。“虽然我们的先进外骨骼技术平台已经处于行业领先地位，但在某些方面，随着我们致力于构建并利用我们认为将是业界首个已知的物理康复人体运动基础模型时，我们才刚刚接近起跑线。”

We are excited for this journey with NVIDIA Connect and look forward to updating all of our stakeholders as we progress.”.

我们对与NVIDIA Connect的合作旅程感到兴奋，并期待在我们取得进展的过程中向所有利益相关者更新信息。

About Ekso Bionics

关于Ekso Bionics

®

®

Ekso Bionics

Ekso Bionics

®

®

is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance and mobility across medical and industrial applications. Based upon its industry-leading expertise, the Company focuses on improving health and quality of life with advanced robotics designed to enhance, amplify, and restore human function.

是一家领先的外骨骼解决方案开发商，通过支持或增强医疗和工业应用中的力量、耐力和移动性来放大人类潜能。基于其行业领先的专业知识，该公司专注于通过先进的机器人技术改善健康和生活质量，这些技术旨在增强、放大和恢复人体功能。

Ekso Bionics is the only known exoskeleton company to offer technologies that range from helping those with paralysis to stand up and walk, to enhancing human capabilities on job sites across the globe. The Company is headquartered in the San Francisco Bay Area and is listed on the Nasdaq Capital Market under the symbol “EKSO.” For more information, visit: .

Ekso Bionics 是唯一已知的外骨骼公司，其技术范围从帮助瘫痪患者站立和行走，到增强全球工作现场的人类能力。公司总部位于旧金山湾区，并在纳斯达克资本市场上市，股票代码为“EKSO”。欲了解更多信息，请访问：。

www.eksobionics.com

www.eksobionics.com

.

。

Forward-Looking Statements

前瞻性声明

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding the plans, objectives and expectations of management with respect to the Company’s industry, growth and strategy, including the Company’s plan to build a proprietary model for human motion and the expected benefits of AI capabilities and being a part of the NVIDIA Connect program.

本新闻稿中包含的任何非描述历史事实的陈述可能构成前瞻性陈述。前瞻性陈述包括但不限于有关公司管理层对公司行业、增长和战略的计划、目标和期望的陈述，包括公司构建人体运动专有模型的计划以及对人工智能能力的预期效益和参与NVIDIA Connect计划的预期好处的陈述。

Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over.

此类前瞻性陈述并非旨在预测或保证实际结果、业绩、事件或情况，且可能无法实现，因为它们基于公司的当前预测、计划、目标、信念、预期、估计和假设，并受许多风险和不确定性及其他影响因素的制约，其中许多因素公司无法控制。

Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to realize the benefits of the NVIDIA Connect program or successfully complete the building of a proprietary model for human motion, the Company’s inability develop and integrate related new AI capabilities across its portfolio, the Company’s inability to obtain adequate financing to fund and grow the Company's operations and necessary to develop or enhance the Company’s technology, the Company’s inability to successfully collaborate with its network of existing neuro-rehabilitation fa.

实际结果和某些事件及情况的时间安排可能因这些风险和不确定性而与前瞻性陈述中描述的内容存在重大差异。可能导致前瞻性陈述不准确或导致实际结果与预期或期望的结果存在重大差异的因素包括但不限于：公司无法实现NVIDIA Connect计划的效益或成功构建人体运动的专有模型，公司无法在其产品组合中开发和整合相关的新人工智能能力，公司无法获得充足的资金来推动和支持公司运营及发展或提升公司技术，公司无法成功与其现有的神经康复网络合作。

Contact:

联系人：

Stephen Kilmer

斯蒂芬·基尔默

Investor Relations

投资者关系

Direct: (646) 274-3580

直线电话：（646）274-3580

Email:

电子邮件：

skilmer@eksobionics.com

skilmer@eksobionics.com

Released May 15, 2025

发布于2025年5月15日